UroGen invests up to $7 million in IntraGel equity

• UroGen Pharma entered an equity investment agreement with IntraGel Therapeutics to invest up to $7 million in IntraGel securities.
• Investment ties to a strategic collaboration granting options to license IntraGel’s SRGel platform for up to three oncology products.
• Separate option covers worldwide rights to TumoCure for advanced head and neck cancer, exercisable following completion of a Phase 2 study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200700PRIMZONEFULLFEED9813414) on August 20, 2026, and is solely responsible for the information contained therein.